IL-17A and IL-17F are both proinflammatory cytokines that drive the pathophysiology of immune-mediated inflammatory diseases including plaque psoriasis and psoriatic arthritis. While earlier biologics targeted IL-17A alone — such as secukinumab (Cosentyx) from Novartis and ixekizumab — the IL-17A/F heterodimer also plays a significant role in disease pathology. Agents that block all three molecular species (IL-17A homodimer, IL-17F homodimer, and IL-17A/F heterodimer) may offer broader suppression of the inflammatory axis.

Izokibep (ABY-035), developed by Affibody AB and partnered with Acelyrin Inc., is an Affibody molecule consisting of three domains: two domains that bind to IL-17A and IL-17F respectively, and a third albumin binding domain (ABD) that binds to albumin for half-life extension. This tripartite architecture enables subcutaneous administration while maintaining therapeutic half-life — a key advantage over large-format monoclonal antibodies.

The small molecular format of izokibep also confers improved tissue penetration compared to conventional antibodies, as described in nanobody construct patents from Ablynx NV and Argenx BV. This property is particularly relevant for inflamed joint tissue in psoriatic arthritis, where deep tissue access may correlate with clinical response. Improvements in inflammatory biomarkers including C-reactive protein (CRP) and interleukin-6 (IL-6) have been reported in patent-described clinical outcomes for izokibep-treated patients.

For R&D teams and IP professionals tracking the life sciences biologic landscape, izokibep represents a structurally distinct competitive entry that cannot be analysed through the same lens as conventional IgG biologics. Understanding its patent architecture is essential for freedom-to-operate and competitive intelligence.

The albumin binding domain (ABD) strategy that underpins izokibep's half-life extension is protected by Affibody AB's WO2019110578A1 — a fusion protein patent covering Affibody molecules combined with an albumin binding domain, filed in 2019 and now carrying 20 citations. This foundational patent covers the general principle of combining two or more Affibody molecules with an ABD for half-life extension, making it a key piece of prior art for any competitor attempting to use a similar small-format approach.

The earlier Affibody molecule patent WO2015118026A1 (2015, 20 citations) covers Affibody molecules binding to IL-17A specifically, establishing the foundational binding sequences (SEQ ID NO: 1–37) for the IL-17A targeting domain of izokibep. Together, these two platform patents create a layered IP position that protects both the binding specificity and the half-life extension mechanism.

For IP teams conducting freedom-to-operate analysis or competitive landscape work in the small-format biologic space, these platform patents — and their citation networks — are essential starting points. The European Patent Office and USPTO prosecution histories for these filings reveal the claim scope boundaries that competitors must navigate. PatSnap Eureka enables rapid citation network traversal and claim mapping across all jurisdictions.

Life sciences teams tracking biologic pipeline intelligence should note that the Affibody platform is not limited to IL-17 targets — the ABD fusion strategy is applicable to any Affibody molecule, meaning Affibody AB's platform IP has broader competitive implications beyond the psoriasis and PsA space.